面对前列腺癌这一男性泌尿系统高发肿瘤，传统雄激素剥夺治疗 (ADT)虽是基石，但"大多数患者在接受ADT后约1年内进展为去势抵抗性前列腺癌" [1]。近年来，新型内分泌治疗药物的问世为临床带来革命性突破，显著延长患者生存期并改善生活质量。

ADT has been treading water for the past six months, recording a small loss of 2.3% while holding steady at $8.24. The stock ...

The transaction supports ADT’s journey to be the premier provider of smart home and residential solar solutions by leveraging our strategic differentiators: innovative offerings, unrivaled safety and ...

ADT Inc. reported strong financial performance in the first quarter of 2025, achieving a total revenue increase of 7% to $1.3 billion and a 2% rise in recurring monthly revenue to $360 million. The ...

This article first appeared on GuruFocus. ADT Inc (NYSE:ADT) is set to release its Q3 2025 earnings on November 4, 2025. The consensus estimate for Q3 2025 revenue is $1.29 billion, and the earnings ...

Entirety of net proceeds used for debt paydown, resulting in post-divestiture leverage multiples closer to ADT’s stated goal of sub-3.0x net debt / Adjusted EBITDA ADT strengthens focus on innovation ...

ADT Inc. (NYSE:ADT) shares are trading higher Thursday after the company reported financial results for the third quarter of 2024. Here’s what you need to know. What To Know: ADT reported ...

ADT reports fourth-quarter revenue of $1.3 billion, beating analyst estimates of $1.23 billion. ADT reports fourth-quarter adjusted earnings of 20 cents per share, beating analyst estimates of 19 ...